La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Orchid Pharma Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Orchid Pharma ha un patrimonio netto totale di ₹11.7B e un debito totale di ₹1.4B, che porta il suo rapporto debito/patrimonio netto a 11.6%. Le sue attività totali e le sue passività totali sono rispettivamente ₹15.5B e ₹3.8B. L'EBIT di Orchid Pharma è ₹872.4M rendendo il suo rapporto di copertura degli interessi -42.8. Ha liquidità e investimenti a breve termine pari a ₹36.2M.

Informazioni chiave

11.6%

Rapporto debito/patrimonio netto

₹1.35b

Debito

Indice di copertura degli interessi	-42.8x
Contanti	₹36.16m
Patrimonio netto	₹11.69b
Totale passività	₹3.84b
Totale attività	₹15.54b

Aggiornamenti recenti sulla salute finanziaria

Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?

Feb 06

Recent updates

Earnings Tell The Story For Orchid Pharma Limited (NSE:ORCHPHARMA) As Its Stock Soars 26%

Jul 29

We Ran A Stock Scan For Earnings Growth And Orchid Pharma (NSE:ORCHPHARMA) Passed With Ease

Jun 12

Orchid Pharma Limited's (NSE:ORCHPHARMA) Intrinsic Value Is Potentially 17% Below Its Share Price

May 08

Orchid Pharma Limited's (NSE:ORCHPHARMA) P/S Is Still On The Mark Following 72% Share Price Bounce

Feb 28

Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?

Feb 06

Orchid Pharma Limited (NSE:ORCHPHARMA) Looks Just Right With A 33% Price Jump

Dec 18

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ₹7.9B ) di ORCHPHARMA superano le sue passività a breve termine ( ₹2.6B ).

Passività a lungo termine: Le attività a breve termine di ORCHPHARMA ( ₹7.9B ) superano le sue passività a lungo termine ( ₹1.2B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 11.3% ) di ORCHPHARMA è considerato soddisfacente.

Riduzione del debito: Cinque anni fa, ORCHPHARMA aveva un patrimonio netto negativo, ma ora è positivo e quindi è migliorato.

Copertura del debito: Il debito di ORCHPHARMA è ben coperto dal flusso di cassa operativo ( 93.2% ).

Copertura degli interessi: ORCHPHARMA matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.

Orchid Pharma Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?

Recent updates

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 21% undervalued

Earnings Tell The Story For Orchid Pharma Limited (NSE:ORCHPHARMA) As Its Stock Soars 26%

Orchid Pharma Limited to Report Q4, 2025 Results on May 30, 2025

Orchid Pharma Limited, Annual General Meeting, Aug 21, 2024

Orchid Pharma Limited, Annual General Meeting, Aug 21, 2024

Investor sentiment improves as stock rises 24%

We Ran A Stock Scan For Earnings Growth And Orchid Pharma (NSE:ORCHPHARMA) Passed With Ease

Orchid Pharma Receives DCGI Approval for Its First Invented and Made-In-India Antibiotic Drug Combination of Cefepime and Enmetazobactam

Now 20% undervalued after recent price drop

Orchid Pharma Limited Appoints Shubha Singh as Additional Director

Orchid Pharma Limited to Report Q4, 2024 Results on May 23, 2024

Orchid Pharma Limited's (NSE:ORCHPHARMA) Intrinsic Value Is Potentially 17% Below Its Share Price

Orchid Pharma Limited Announces Resignation of Mudit Tandon as Independent Director

Now 25% overvalued after recent price rise

Orchid Pharma Limited's (NSE:ORCHPHARMA) P/S Is Still On The Mark Following 72% Share Price Bounce

Investor sentiment improves as stock rises 27%

Now 29% overvalued after recent price rise

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?

Orchid Pharma Limited to Report Q3, 2024 Results on Feb 08, 2024

European Medicines Agency Grants Approval for Orchid Pharma's 'Exblifep'

Investor sentiment improves as stock rises 20%

Orchid Pharma Limited (NSE:ORCHPHARMA) Looks Just Right With A 33% Price Jump

Orchid Pharma Limited Appoints Kapil Dayya as Company Secretary & Compliance Officer

Orchid Pharma Limited Announces Resignation of Marina Peter as Company Secretary and Compliance Officer

Second quarter 2024 earnings released: EPS: ₹4.30 (vs ₹1.32 loss in 2Q 2023)

Orchid Pharma Limited to Report Q2, 2024 Results on Nov 04, 2023

Orchid Pharma Limited Approves the Appointment of Mr. Arjun Dhanuka as Additional Director (In Capacity of Non-Executive & Non-Independent)

Orchid Pharma Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings released: EPS: ₹13.01 (vs ₹14.80 loss in FY 2022)

Investor sentiment improves as stock rises 16%

Orchid Pharma Limited, Annual General Meeting, Aug 09, 2023

Insufficient new directors

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 15%

Full year 2023 earnings released: EPS: ₹13.01 (vs ₹14.80 loss in FY 2022)

Third quarter 2023 earnings released: EPS: ₹1.86 (vs ₹2.59 loss in 3Q 2022)

Orchid Pharma Limited Announces Demise of Arun Kumar Dhanuka, Non-Executive & Non-Independent Director

Second quarter 2023 earnings released

High number of new and inexperienced directors

Orchid Pharma Limited Announces Appointment of Marina Peter as Company Secretary and Compliance Officer

Now 21% undervalued

First quarter 2023 earnings released: ₹3.68 loss per share (vs ₹6.93 loss in 1Q 2022)

Orchid Pharma Limited to Report Q1, 2023 Results on Aug 10, 2022

Orchid Pharma Limited Announces Resignation of Nikita as Company Secretary and Compliance Officer

Now 22% undervalued after recent price drop

Full year 2022 earnings released

Orchid Pharma Limited, Annual General Meeting, Jul 15, 2022

Now 23% undervalued

Orchid Pharma Limited to Report Q4, 2022 Results on May 12, 2022

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

New 90-day high: ₹823

Third quarter 2021 earnings released: ₹10.96 loss per share (vs ₹959 loss in 3Q 2020)

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane